Live symbol workspace

ABBV market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $208.84

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$198.40

Resistance

$219.28

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$208.84

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Over the last 30 days, AI sentiment for ABBV skewed neutral (2 of 3 scored calls).

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

30%

▼ 14.0 pts vs previous week

Avg confidence across 12 calls in the last 7 days

What sources say

Neutral 2 articles

AI Perfection Fuels a Return to Looking Human

2 Reasons to Like ABBV and 1 to Stay Skeptical

Bullish 1 article

The Engine Behind ABBV Stock Has Real Parts

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

ABBV News Intelligence (11 articles)

AI-curated news influencing ABBV price, sentiment, and trend

Explore All ABBV News with AI Analysis

Economy

3 months ago

2 Reasons to Like ABBV and 1 to Stay Skeptical

Over the past six months, AbbVie’s shares (currently trading at $211.15) have posted a disappointing 9.8% loss, well below the …

Impact on ABBV: Neutral market sentiment indicated

Financial market analysis indicating neutral sentiment based on current trends. Medium (50%)

View full analysis →

Yahoo Finance 50% confidence

Economy

3 months, 3 weeks ago

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading session that saw all major indices …

Impact on ABBV: The unchanged interest rates may lead to a short-term boost in stock …

Wall Street analyst research calls for Thursday feature updates on several major stocks, including AbbVie, … Medium (60%)

View full analysis →

Yahoo Finance 60% confidence

Economy

4 months ago

AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development

AbbVie Inc. (NYSE:ABBV) is one of the top S&P 500 stocks by index weight. On April 13, AbbVie Inc. (NYSE:ABBV) …

Impact on ABBV: Neutral market sentiment indicated

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence. High (94%)

View full analysis →

Yahoo Finance 94% confidence

Stocks

4 months, 2 weeks ago

Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.

Soleno Therapeutics stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy …

Impact on ABBV: Soleno Therapeutics' stock is soaring in premarket trading, with potential for a …

Neurocrine's potential acquisition of Soleno Therapeutics is driving a surge in Soleno's stock price, with … High (80%)

View full analysis →

MarketWatch 80% confidence

Economy

5 months ago

Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now

AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation.

Impact on ABBV: AbbVie's (ABBV) undervaluation could lead to a price increase, potentially driving the …

AbbVie's strong financials, attractive dividend, and modest valuation make its stock appear undervalued, presenting a … High (70%)

View full analysis →

Yahoo Finance 70% confidence